← Eichor
Study identifier: NCT05066308 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cannabidiol for Reduction of Brain Neuroinflammation

Condition: Back Pain · Depressive Symptoms  ·  Sponsor: Massachusetts General Hospital

PhasePhase 2
Planned participants80
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.

This description comes directly from the study's public registry record.

Talk to the study team

Jodi M Gilman, PhD  ·  617-643-7293  ·  jgilman1@mgh.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05066308